Literature DB >> 14566450

Quantitative measurement of depolarization-induced anandamide release in human and rat neocortex.

Marc Steffens1, Thomas J Feuerstein, Vera van Velthoven, Peter Schnierle, Rainer Knörle.   

Abstract

It has been suggested that the endocannabinoid anandamide is released from central neurons upon depolarization of the cell membrane. In order to determine whether anandamide levels were increased after K(+) depolarization of fresh human and rat brain slices, we developed a rapid and sensitive method for the isolation and quantitation of anandamide. This included solvent extraction, solid phase separation, and reversed phase high performance liquid chromatography (HPLC) with fluorometric detection. Compared with basal levels, K(+) stimulation enhanced the neocortical anandamide concentration in both species (70.5 vs. 21.1 pmol/g tissue in humans, 14.3 vs. 3.2 pmol/g tissue in rats). Basal anandamide levels in the rat hippocampus (11.1 pmol/g) were significantly higher than in the neocortex. Anandamide was also detected in the human amygdala (67.8 pmol/g). In conclusion, our data provide evidence for the depolarization-induced synthesis of anandamide, supporting the hypothesis of a neuromodulatory action of this endocannabinoid. Furthermore, the presence of anandamide in the limbic system suggests participation in cognition, behavior or reward.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14566450     DOI: 10.1007/s00210-003-0817-1

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  25 in total

1.  Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A.

Authors:  G L Gessa; M S Mascia; M A Casu; G Carta
Journal:  Eur J Pharmacol       Date:  1997-05-26       Impact factor: 4.432

2.  Dopamine activation of endogenous cannabinoid signaling in dorsal striatum.

Authors:  A Giuffrida; L H Parsons; T M Kerr; F Rodríguez de Fonseca; M Navarro; D Piomelli
Journal:  Nat Neurosci       Date:  1999-04       Impact factor: 24.884

Review 3.  Modulation of transmitter release via presynaptic cannabinoid receptors.

Authors:  E Schlicker; M Kathmann
Journal:  Trends Pharmacol Sci       Date:  2001-11       Impact factor: 14.819

4.  Flavonoids with epidermal growth factor-receptor tyrosine kinase inhibitory activity stimulate PEPT1-mediated cefixime uptake into human intestinal epithelial cells.

Authors:  U Wenzel; S Kuntz; H Daniel
Journal:  J Pharmacol Exp Ther       Date:  2001-10       Impact factor: 4.030

5.  Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration.

Authors:  H H Hansen; P C Schmid; P Bittigau; I Lastres-Becker; F Berrendero; J Manzanares; C Ikonomidou; H H Schmid; J J Fernández-Ruiz; H S Hansen
Journal:  J Neurochem       Date:  2001-09       Impact factor: 5.372

6.  Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function.

Authors:  T Bisogno; F Berrendero; G Ambrosino; M Cebeira; J A Ramos; J J Fernandez-Ruiz; V Di Marzo
Journal:  Biochem Biophys Res Commun       Date:  1999-03-16       Impact factor: 3.575

7.  Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A.

Authors:  A N Gifford; C R Ashby
Journal:  J Pharmacol Exp Ther       Date:  1996-06       Impact factor: 4.030

8.  Isotope dilution mass spectrometric measurements indicate that arachidonylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from fresh tissue.

Authors:  K Kempe; F F Hsu; A Bohrer; J Turk
Journal:  J Biol Chem       Date:  1996-07-19       Impact factor: 5.157

9.  Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat.

Authors:  C C Felder; A Nielsen; E M Briley; M Palkovits; J Priller; J Axelrod; D N Nguyen; J M Richardson; R M Riggin; G A Koppel; S M Paul; G W Becker
Journal:  FEBS Lett       Date:  1996-09-16       Impact factor: 4.124

10.  Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent.

Authors:  E Fride; R Mechoulam
Journal:  Eur J Pharmacol       Date:  1993-02-09       Impact factor: 4.432

View more
  3 in total

Review 1.  More surprises lying ahead. The endocannabinoids keep us guessing.

Authors:  Daniele Piomelli
Journal:  Neuropharmacology       Date:  2013-08-13       Impact factor: 5.250

2.  Exogenous and endogenous cannabinoids suppress inhibitory neurotransmission in the human neocortex.

Authors:  Flora E Kovacs; Tim Knop; Michal J Urbanski; Ilka Freiman; Thomas M Freiman; Thomas J Feuerstein; Josef Zentner; Bela Szabo
Journal:  Neuropsychopharmacology       Date:  2011-11-02       Impact factor: 7.853

3.  Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex.

Authors:  M Steffens; C Engler; J Zentner; T J Feuerstein
Journal:  Br J Pharmacol       Date:  2004-03-01       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.